NEJM: Injecting cabotegravir program for pre-exposure prevention of HIV high-risk groups

Although HIV prevention has made significant progress, the number of new HIV infections in the world is still more than 5,000 daily .

Prevention of infection Recently, researchers have investigated the prospects of CAB-LA as a long-term HIV pre-exposure prevention method

This study is a randomized, double-blind, non-inferiority trial.

4566 participants, of which 570 (12.

52 participants had HIV infection events, of which 13 cases were in the cabotegravir group (incidence rate was 0.

Differences in HIV infection risk between groups

Differences in HIV infection risk between groups

Studies believe that in people at high risk of HIV infection, the efficacy of the long-acting injection of cabotegravir pre-exposure prophylaxis is better than the daily oral tenofovir-emtricitabine regimen, but the problem of long-acting integrase inhibitor resistance is worthy of attention

In people at high risk of HIV infection, the efficacy of long-acting injection of cabotegravir pre-exposure prophylaxis is better than that of daily oral tenofovir-emtricitabine, but the problem of long-acting integrase inhibitor resistance is worth paying attention to in HIV infection In high-risk populations, the efficacy of the long-acting injection of cabotegravir pre-exposure prophylaxis is better than the daily oral tenofovir-emtricitabine regimen, but the problem of long-acting integrase inhibitor resistance is worthy of attention

Original source:

Original source:

Raphael J.

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.


Leave a message here